Skip to content
Forensic Analysis · Pharmaceuticals & Biotechnology · as of Nov 11, 2026

Perspective Therapeutics, Inc. (CATX)

A forensic read on Perspective Therapeutics, Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.

D · Weak — demands caution
Forensic grade
Distress
Financial health
-0.4
Distress distance
2
Forensic signals
-41.4%
ROE

This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (auditor quality, say on pay, board independence, going concern). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.

Perspective Therapeutics, Inc. earns a D (Weak — demands caution) forensic quality grade, and its balance-sheet distress test reads -0.4, placing it in the Distress zone. 2 forensic signals were flagged in its latest SEC filings, led by stock-based comp load.

What the filings flag

261% of rev
FY2023
Stock-based comp load. Stock-based compensation ran 261% of revenue in FY2023 — about $0.14 per diluted share. No cash left the business to pay it, which is why operating cash flow adds it back. Net of repurchases the diluted count still rose about 14.6% a year across FY2024–FY2025, above the level at which the count is a material claim on a stake, and only one year's change is on file — enough to state what a holder gave up, not enough to say whether the rate is climbing or coming down. Stock compensation is one source of that issuance; acquisition consideration, equity raises, convertibles and other employee plans also net into the count, and these figures do not separate them.
$24M
FY2024
Goodwill impairments. Took $24M of goodwill writedowns across 1 year (FY2024 ($24M)). Writedowns mean past acquisitions underperformed what was paid for them.

Key fundamentals

Latest Revenue$1.4M
Net Margin-3243.2%
Free Cash Flow-$95.2M
Return on Equity-41.4%
Debt / Equity0.02x

The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Perspective Therapeutics, Inc.'s actual 10-K/10-Q/8-K filings?

Generate the AI investment read →

No credit card · informational only, not investment advice · see the track record

← Browse all forensic stock analyses

Data from SEC EDGAR public filings · metrics as of Nov 11, 2026. Forensic signals flag probability, not certainty.

See a wrong number? Report an error with the filing it should match.